Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of SMF-216 versus amlodipine in primary mild to moderate hypertension uncontrolled after 4 weeks of amlodipine monotherapy
CTR20263474Phase 3Active
- Sponsor
- Jiangxi Shimei Pharmaceutical
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of levamlodipine + benazepril in essential hypertension (2 arms), sponsored by Jiangxi Shimei Pharmaceutical. Primary endpoint: Change from baseline in trough seated diastolic blood pressure after 8 weeks of randomized double-blind treatment. Started Sep 2026; status: active.
02
Drugs
levamlodipine + benazepril
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20263474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263474.